Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Oncopeptides Ord Shs ONPPF

Oncopeptides AB is a Sweden-based biotech company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The Company’s lead product candidate PEPAXTO (melphalan flufenamide, also known as melflufen) has been approved in relapsed or refractory multiple myeloma by The U.S. Food and Drug Administration. Melphalan flufenamide is the first drug originated... see more

Recent & Breaking News (GREY:ONPPF)

    Number of shares and votes in Oncopeptides

    PR Newswire July 29, 2022

    FDA announces an Oncologic Drugs Advisory Committee meeting to discuss benefit/risk profile of Oncopeptides' Pepaxto

    PR Newswire July 20, 2022

    Oncopeptides rescinds voluntary withdrawal of Pepaxto in the US - no intent to market in the US at this time

    PR Newswire January 21, 2022

    Oncopeptides presents phase 3 OCEAN study results at the IMW meeting

    PR Newswire September 11, 2021

    Bulletin from the Annual General Meeting in Oncopeptides AB (publ)

    PR Newswire May 26, 2021

    Oncopeptides completes patient enrollment in phase 2 PORT study

    PR Newswire May 5, 2021

    Oncopeptides publishes the 2020 Annual Report

    PR Newswire April 26, 2021

    Oncopeptides submits application for conditional marketing authorization of melflufen in the EU

    PR Newswire April 16, 2021

    Number of shares and votes in Oncopeptides

    PR Newswire March 31, 2021

    Oncopeptides announces that the first patients in the United States are being treated with PEPAXTO®

    PR Newswire March 15, 2021